PE20210651A1 - Vacunas contra virus de la gripe y usos de las mismas - Google Patents

Vacunas contra virus de la gripe y usos de las mismas

Info

Publication number
PE20210651A1
PE20210651A1 PE2020000984A PE2020000984A PE20210651A1 PE 20210651 A1 PE20210651 A1 PE 20210651A1 PE 2020000984 A PE2020000984 A PE 2020000984A PE 2020000984 A PE2020000984 A PE 2020000984A PE 20210651 A1 PE20210651 A1 PE 20210651A1
Authority
PE
Peru
Prior art keywords
vaccines against
flu viruses
against flu
polypeptides
viruses
Prior art date
Application number
PE2020000984A
Other languages
English (en)
Inventor
Ferdinand Jacobus Milder
Tina Ritschel
Boerries Brandenburg
Mandy Antonia Catharina Jongeneelen
Daphne Truan
Johannes Petrus Maria Langedijk
Original Assignee
Janssen Vaccines And Prevention B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Vaccines And Prevention B V filed Critical Janssen Vaccines And Prevention B V
Publication of PE20210651A1 publication Critical patent/PE20210651A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan polipeptidos de tallo de la hemaglutinina de la gripe, acidos nucleicos que codifican dichos polipeptidos, vectores que comprenden dicho acido nucleico y composiciones farmaceuticas que los comprenden, asi como metodos de su uso, en particular en la prevencion y/o tratamiento de infecciones por virus de la gripe
PE2020000984A 2018-01-23 2019-01-22 Vacunas contra virus de la gripe y usos de las mismas PE20210651A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18152991 2018-01-23
PCT/EP2019/051532 WO2019145310A1 (en) 2018-01-23 2019-01-22 Influenza virus vaccines and uses thereof

Publications (1)

Publication Number Publication Date
PE20210651A1 true PE20210651A1 (es) 2021-03-26

Family

ID=61094216

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2020000984A PE20210651A1 (es) 2018-01-23 2019-01-22 Vacunas contra virus de la gripe y usos de las mismas

Country Status (26)

Country Link
US (2) US11447526B2 (es)
EP (2) EP4119154A1 (es)
JP (1) JP7317047B2 (es)
KR (1) KR20200113226A (es)
CN (1) CN111655284B (es)
AU (1) AU2019212180A1 (es)
BR (1) BR112020014343A2 (es)
CA (1) CA3089177A1 (es)
CL (1) CL2020001901A1 (es)
DK (1) DK3743106T3 (es)
EA (1) EA202091769A1 (es)
ES (1) ES2926243T3 (es)
HR (1) HRP20220980T1 (es)
HU (1) HUE059545T2 (es)
IL (2) IL294797B2 (es)
LT (1) LT3743106T (es)
MX (1) MX2020007777A (es)
PE (1) PE20210651A1 (es)
PH (1) PH12020500569A1 (es)
PL (1) PL3743106T3 (es)
PT (1) PT3743106T (es)
RS (1) RS63526B1 (es)
SG (1) SG11202006399VA (es)
SI (1) SI3743106T1 (es)
WO (1) WO2019145310A1 (es)
ZA (1) ZA202004538B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115038713A (zh) * 2019-10-15 2022-09-09 扬森疫苗与预防公司 流感病毒疫苗及其用途
WO2021249013A1 (en) * 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Vaccine compositions, methods, and uses thereof
JP2023166633A (ja) * 2020-09-30 2023-11-22 キリンホールディングス株式会社 インフルエンザウイルス抑制用の融合タンパク質およびこれを含む医薬組成物
CN114891074B (zh) * 2022-05-10 2023-04-11 中山大学·深圳 一种季节性甲型流感通用病毒样颗粒及其制备方法与应用
CN116589566A (zh) * 2022-11-18 2023-08-15 昆明医科大学第一附属医院 一种HIV-1中和抗体的改造重组单克隆IgM抗体及其应用
GB202219228D0 (en) * 2022-12-20 2023-02-01 Glaxosmithkline Biologicals Sa Novel influenza antigens

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
CA2192442C (en) 1994-06-10 2007-09-25 Imre Kovesdi Complementary adenoviral vector systems and cell lines
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
US5965541A (en) 1995-11-28 1999-10-12 Genvec, Inc. Vectors and methods for gene transfer to cells
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US5994128A (en) 1995-06-15 1999-11-30 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
US6020191A (en) 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
EP2059532B1 (en) 2006-09-07 2012-12-26 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
WO2010010467A2 (en) * 2008-07-25 2010-01-28 Institute For Research In Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof
CA2787099A1 (en) 2009-03-30 2010-10-14 Anice C. Lowen Influenza virus hemagglutinin polypeptides containing stem domains, vaccines and uses thereof
NZ596032A (en) 2009-05-11 2013-09-27 Crucell Holland Bv Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof
EP3248615A1 (en) 2010-03-30 2017-11-29 Mount Sinai School of Medicine of New York University Influenza virus vaccines and uses thereof
EP2731967B1 (en) 2011-07-14 2016-10-12 Janssen Vaccines & Prevention B.V. Human binding molecules capable of neutralizing influenza a viruses of phylogenetic group 1 and phylogenetic group 2 and influenza b viruses
AU2012343981B2 (en) 2011-11-28 2017-09-07 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
JP6643981B2 (ja) 2013-05-30 2020-02-12 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． インフルエンザウイルスワクチンおよびその使用
EP3805254A1 (en) * 2013-08-03 2021-04-14 Calder Biosciences Inc. Methods of making and using influenza virus hemagglutinin complexes
MX2017000394A (es) 2014-07-10 2017-11-30 Janssen Vaccines & Prevention Bv Vacunas para virus influenza y usos de las mismas.
BR112016030577A8 (pt) * 2014-07-10 2021-07-20 Janssen Vaccines & Prevention Bv polipeptídeos multiméricos do domínio de haste da hemaglutinina da gripe, molécula de ácido nucleico, vetor, composição e usos destes

Also Published As

Publication number Publication date
PL3743106T3 (pl) 2022-11-14
PT3743106T (pt) 2022-08-24
IL294797A (en) 2022-09-01
MX2020007777A (es) 2020-09-18
US20220411474A1 (en) 2022-12-29
JP2021511077A (ja) 2021-05-06
US11905314B2 (en) 2024-02-20
WO2019145310A1 (en) 2019-08-01
ZA202004538B (en) 2023-01-25
IL294797B2 (en) 2024-06-01
SG11202006399VA (en) 2020-08-28
EP4119154A1 (en) 2023-01-18
BR112020014343A2 (pt) 2020-12-08
CN111655284A (zh) 2020-09-11
ES2926243T3 (es) 2022-10-24
EP3743106B1 (en) 2022-06-15
JP7317047B2 (ja) 2023-07-28
CA3089177A1 (en) 2019-08-01
EP3743106A1 (en) 2020-12-02
CL2020001901A1 (es) 2020-10-23
PH12020500569A1 (en) 2021-05-10
SI3743106T1 (sl) 2022-10-28
LT3743106T (lt) 2022-09-26
EA202091769A1 (ru) 2020-10-16
HRP20220980T1 (hr) 2022-11-11
RS63526B1 (sr) 2022-09-30
US11447526B2 (en) 2022-09-20
IL275849B (en) 2022-09-01
HUE059545T2 (hu) 2022-11-28
CN111655284B (zh) 2024-06-11
IL294797B1 (en) 2024-02-01
US20200377555A1 (en) 2020-12-03
KR20200113226A (ko) 2020-10-06
AU2019212180A1 (en) 2020-07-16
DK3743106T3 (da) 2022-09-05
IL275849A (en) 2020-08-31

Similar Documents

Publication Publication Date Title
PE20210651A1 (es) Vacunas contra virus de la gripe y usos de las mismas
CL2017001798A1 (es) Compuestos de pirazina para el tratamiento de enfermedades infecciosas.
EP4233898A3 (en) Influenza mrna vaccines
CL2018002825A1 (es) Vacuna contra vrs
MX2020004830A (es) Medios y metodo para preparar vectores virales y usos de los mismos.
BR112015014482A2 (pt) vacinas para vírus influenza e seus usos
BR112016030577A2 (pt) vacinas contra o vírus da gripe e usos das mesmas
CO2017011535A2 (es) Composiciones de ácido obeticólico y métodos de uso
EA201792500A1 (ru) Aav-опосредованная экспрессия антител против гриппа и способы их использования
CL2018000740A1 (es) Vectores del factor viii del virus adeno-asociado, partículas víricas asociadas y formulaciones terapéuticas que los comprenden
CL2018002874A1 (es) Anticuerpos de hemaglutinina contra el virus de la influenza b y métodos de uso (divisional de solicitud n° 2413-2016).
ES2682981T3 (es) Proteínas de hemaglutinina del virus de la gripe y método de uso de las mismas
BR112017000257A2 (pt) vacinas contra o vírus da gripe e usos das mesmas
AR102547A1 (es) Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
EP3939604A3 (en) Influenza hemagglutinin protein vaccines
CL2018001742A1 (es) Compuestos indolinones y sus usos en el tratamiento de enfermedades fibroticas.
NZ739260A (en) Inactivated canine influenza vaccines and methods of making and uses thereof
AR101814A1 (es) Partícula de tipo virus flavivirus
MX2022002766A (es) Vacunas contra el virus de la gripe y usos de las mismas.
CO7461135A2 (es) Parvovirus porcino 5b, métodos de uso y vacuna
EA201400235A1 (ru) Вакцины против гриппа на основе н5
AR094846A1 (es) Proteínas h5 del virus de la gripe h5n1 para uso como un medicamento
EA201991319A1 (ru) Вакцины аттенуированного свиного гриппа и способы их изготовления и применения
EA201892385A1 (ru) Модификация сконструированных полипептидов гемагглютинина вируса гриппа
BR112022007253A2 (pt) Vacinas contra o vírus influenza e usos das mesmas